Board Of Directors

Ralph Laufer, PhD

Board Member

Ralph Laufer, PhD

Board Member

Ralph Laufer is Senior Vice President and Head of Discovery and Product Development (DPD) at Teva Pharmaceuticals. He has 20 + years' experience in the pharma industry, much of it as Head of Pharmacology at IRBM, the Rome site of Merck Research Laboratories. For his role in the discovery of Isentress™, first-in-class inhibitor of HIV integrase and winner of the Prix Galien USA 2008 as best pharmaceutical agent, Ralph received the American Chemical Society Heroes of Chemistry Award 2013. He joined Teva R&D from IRBM Science Park, a spin-off of MRL Rome. There, as Scientific Director, Ralph led the development of IRBM's drug discovery strategy and pipeline of proprietary assets. Ralph holds a PhD summa cum laude  in Biochemistry from The Hebrew University of Jerusalem and undertook postdoctoral training at the Institut Pasteur in Paris. He is the author of over 80 peer-reviewed articles and inventor on over 15 patents.

Bob Carpenter, MS, MBA

Co-Founder and Board Member

Bob Carpenter, MS, MBA

Co-Founder and Board Member

Mr. Carpenter is a leader and pioneer in the healthcare and biotechnology industries. He served on Genzyme’s Board of Directors from 1994-2011 and was Executive Vice President of Genzyme from 1989-1991 as well as chairman of its subsidiary IG Laboratories. He founded and served in executive management and board roles at numerous biotech companies, including Integrated Genetics and GelTex Pharmaceuticals, both of which merged with Genzyme, and VacTex, which was acquired by Aquila Biopharmaceuticals. Mr. Carpenter is currently chairman of Hydra Biosciences. Mr. Carpenter is a graduate of West Point. He earned his masters in computer science from Stanford University and his MBA from Harvard Business School.

Asaph Naaman

Board Member

Asaph Naaman

Board Member

Asaph Naaman serves as the Chief Financial Officer for Teva Global R&D, sitting on the leadership teams of both Global R&D and the Global Finance group and overseeing a budget in excess of $1.3 billion for an organization of more than 3000 people. At Teva, Asaph leads the Finance R&D team in all Finance Business Partnership activities and plays an instrumental role in the evaluation and prioritization of R&D projects and other key initiatives.  He is pivotal in the business and financial planning process for Teva Global R&D, including alternative funding programs. Prior to joining Teva, Asaph served as VP Global Corporate Development & Strategy in Better Place, having previously spent 12 years at FMCG giant, Proctor & Gamble, in various finance and BD roles, including Deal Manager, Corporate Mergers & Acquisitions. Asaph Holds an Executive MBA degree from Northwestern University and Tel Aviv University and a BA degree in Economics and Management from Tel Aviv University.

Ben Zeskind, PhD, MBA

Co-Founder and CEO

Ben Zeskind, PhD, MBA

Co-Founder and CEO

Dr. Zeskind is our co-founder and CEO. Over the past seven years, he and his colleagues have established Immuneering as a trusted advisor to leading pharmaceutical companies, pioneering new ways to use biological data for the benefit of patients. Dr. Zeskind is an inventor on numerous patents assigned to both Immuneering's clients and the company itself, and he has published extensively in peer-reviewed journals. He trained at the Massachusetts Institute of Technology, earning a Ph.D. in Bioengineering in 2006 and an SB in Electrical Engineering and Computer Science in 2003. He also earned an MBA at Harvard Business School, where he was recognized as a Baker Scholar, the highest award for distinction.

Scientific Advisory Board

Doug Lauffenburger, PhD, Professor of Biological Engineering, MIT

Co-chair, Scientific Advisory Board

Doug Lauffenburger, PhD, Professor of Biological Engineering, MIT

Co-chair, Scientific Advisory Board

Dr. Lauffenburger is the head of the Department of Biological Engineering at the Massachusetts Institute of Technology and a pioneer in applying engineering principles to biological research. His expertise spans multiple disciplines including chemical engineering, bioengineering, biotechnology process engineering, biophysics, quantitative cell and structural biology, systems biology, and applied mathematics. He has filed numerous patents, authored a key textbook on receptor-ligand binding and trafficking dynamics, and published more than 200 peer-reviewed articles.

Max Artyomov, Ph.D., Assistant Professor of Immunology and Pathology, Washington University

Co-chair, Scientific Advisory Board

Max Artyomov, Ph.D., Assistant Professor of Immunology and Pathology, Washington University

Co-chair, Scientific Advisory Board

Dr. Artyomov is an Assistant Professor of Immunology and Pathology at Washington University in St. Louis. His research is focused on developing an integrated experimental and computational pipeline to address important biological problems by leveraging the power of next-generation sequencing. His approach combines the power of systems immunology with high-throughput sequencing, mathematical modeling and statistical physics. Dr. Artyomov conducted his postdoctoral research at the Broad Institute of Harvard and MIT and earned a Ph.D. in chemistry at the Massachusetts Institute of Technology, with a focus on computational immunology.

Neda Bagheri, Ph.D., Assistant Professor of Chemical and Biological Engineering, Northwestern University

Scientific Advisory Board Member

Neda Bagheri, Ph.D., Assistant Professor of Chemical and Biological Engineering, Northwestern University

Scientific Advisory Board Member

Dr. Bagheri is an Assistant Professor of Chemical and Biological Engineering at the McCormick School of Engineering and Applied Science at Northwestern University. Her research focuses on computational systems biology and complex regulatory networks and their applications to immunology, cancer, and circadian rhythms. Dr. Bagheri conducted her postdoctoral research at the Massachusetts Institute of Technology, and earned her Ph.D. in Electrical and Computer Engineering, with a focus on Control Theory, at the University of California Santa Barbara.

Badri Vardarajan, Assistant Professor of Bioinformatics, Columbia University

Scientific Advisory Board Member

Badri Vardarajan, Assistant Professor of Bioinformatics, Columbia University

Scientific Advisory Board Member

Dr. Vardarajan is an Assistant Professor of Bioinformatics in the Department of Neurology at Columbia University. His research is focused on studying next-generation sequencing techniques in families to find genetic underpinnings of neurological disorders. Dr. Vardarajan is particularly interested in developing novel analytical and bioinformatics tools for rare-variant, gene-gene and gene-environment interaction analyses. He conducted postdoctoral research at Columbia University and earned his Ph.D. in Bioinformatics at Boston University.